在初级心血管预防中风险分层和管理策略的进展
Fotios Barkas1, Yusuf Ziya Sener2, Pelin Arabacilar Golforoush3
1Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
预防动脉样硬化心血管疾病 (ASCVD) 的新战略正在出现. 先进的生物标志物,成像和人工智能改善了风险评估,而新的药物则针对斑块回归,以提供个性化的心血管护理.
科学领域:
- 心血管医学 心血管医学
- 预防性心脏病学 预防性心脏病学
- 生物标志物和诊断方法
背景情况:
- 动脉样性心血管疾病 (ASCVD) 是全球主要的健康负担.
- 目前的ASCVD风险评估工具在预测未来事件方面存在局限性.
- 鉴定患有亚临床动脉样硬化症的个体仍然具有挑战性.
研究的目的:
- 审查ASCVD风险评估和管理的新方法.
- 探索生物标志物,遗传学,成像和人工智能的进展.
- 讨论动脉样硬化预防和斑块回归的干预措施.
主要方法:
- 对生物标志物,遗传学和先进成像学 (例如,冠状动脉评分,CT血管造影) 的最新文献的审查.
- 讨论人工智能在心血管风险分层中的应用.
- 对药理干预的分析,包括他类药物,PCSK9抑制剂和抗炎药物.
主要成果:
- 多基因风险评分和先进的成像学提高了心血管风险分层.
- 新兴干预措施对预防动脉样硬化和促进斑块回归有希望.
- 各种药物的有效性需要进一步研究以获得最佳治疗.
结论:
- 使用新策略的个性化方法可以改善ASCVD初级预防.
- 进一步的研究对于完善干预措施和最大限度地提高其有效性至关重要.
- 进步为保护心血管健康提供了有希望的途径.
更多相关视频
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
相关概念视频
Preventive Healthcare Services
Cardiovascular Drugs: Classification based on Therapeutic Indications
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
